medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2017; 16 (2)


Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma

Guarino M, Picardi M, Vitiello A, Pugliese N, Rea M, Cossiga V, Pane F, Caporaso N, Morisco F

Idioma: Ingles.
Referencias bibliográficas: 62
Paginas: 198-206
Archivo PDF: 165.98 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 2004; 11: 97-107.

  2. Ott J, Stevens G, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-9.

  3. Raimondo G, Pollicino T, Romanò L, Zanetti AR. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris) 2010; 58: 254-7.

  4. Romanò L, Velati C, Cambiè G, Fomiatti L, Galli C, Zanetti AR, SIMTI study group for HBV infection among first-time blood donors. Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infection. Blood Transfus 2013; 11: 281-8.

  5. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-7.

  6. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-70

  7. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-86.

  8. Morisco F, Castiglione F, Rispo A, Stroffolini T, Sansone S, Vitale R, Guarino M, et al. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat 2013; 20: 200-8.

  9. Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, et al. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014; 20: 3516-24.

  10. Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, et al. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014; 17:14-31

  11. Yeo W, Chan P, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.

  12. Huang Y, Lin H, Lee S. Management of chemotherapy-induced hepatitis B virus reactivation. J Chin Med Assoc 2012; 75: 359-62.

  13. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23.

  14. Liang R, Lau G, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999; 17: 394-8.

  15. Yeo W, Johnson P. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.

  16. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-11.

  17. Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L, Baldelli F. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 2010; 38: 58-61.

  18. Yagci M, Ozkurt Z, Yegin Z, Aki Z, Sucak GT, Haznedar R. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Hematology 2010; 15: 240-4.

  19. Sugauchi F, Tanaka Y, Kusumoto S, Matsuura K, Sugiyama M, Kurbanov F, Ueda R, et al. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol 2011; 83: 412-8.

  20. Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, et al. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin’s lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 2003; 88: 1296-303.

  21. Picardi M, De Rosa G, Selleri C, Pane F, Rotoli B, Muretto P. Clinical relevance of intrahepatic hepatitis B virus DNA in HBsAg- negative HBcAb-positive patients undergoing hematopoietic stem cell transplantation for haematological malignancies. Transplantation 2006; 82: 141-2.

  22. Persico M, De Marino F, Russo GD, Morante A, Rotoli B, Torella R, De Renzo A. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002; 99: 724-5.

  23. Huang Y, Lin H, Lee S. Management of chemotherapy-induced hepatitis B virus reactivation. J Chin Med Assoc 2012; 75: 359-62.

  24. Lee I, Huang Y, Chu C, Lee PC, Lin HC, Lee SD. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc 2010; 73: 156-60.

  25. Lau G, Yiu H, Fong D, Cheng HC, Au WY, Lai LS, Cheung M, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-9.

  26. Hsu C, Hsiung C, Su I, Hwang WS, Wang MC, Lin SF, Hsiao HH, et al. A revisit of prophylactic lamivudine for chemotherapy- associated hepatitis B reactivation in non-Hodgkin’s lymphoma: A randomized trial. Hepatology 2008; 47: 844-53.

  27. Hui C, Cheung W, Zhang H, Au WY, Yueng YH, Leung AY, Luk JM, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.

  28. Yeo W, Chan T, Leung N, Lam WY, Mo FK, Chu MT, Chan HL, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.

  29. Koo Y, Tay M, Teh Y, Teng D, Tan DS, Tan IB, Tai DW, et al. Risk of HBV reactivation in hepatitis B surface antigen negative/ hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011; 90: 1219-23.

  30. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189-91.

  31. Czuczman M, Grillo-Lopez A, White C, Saleh M, Gordon L, LoBuglio AF, Jonas C, et al. Treatment of patients with lowgrade B-cell lymphoma with the combination of chimeric anti- CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-76.

  32. Evens A, Jovanovic B, Su Y, Raisch DW, Ganger D, Belknap SM, Dai MS, et al. Rituximab associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Metaanalysis and examination of FDA safety reports. Ann Oncol 2011; 22: 1170-80.

  33. Koo Y, Tan D, Tan I, Tao M, Chow WC, Lim ST. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010; 116: 115-21.

  34. Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B cell lymphoma. Cancer 2010; 116: 4769-76.

  35. Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010; 28: 5097-100.

  36. Pei S, Chen C, Lee C, Wang MC, Ma MC, Hu TH, Kuo CY. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89: 255-61.

  37. Nosotti L, D’Andrea M, Pitidis A, Pimpinelli F, Dessanti ML, Pisani F, Vignally P, et al. Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodg- kin’s lymphoma patients treated with immunochemotherapy. Scand J Infect Dis 2012; 44: 70-3.

  38. Watanabe T, Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatology Research 2013; 43: 113-21.

  39. Dizdar O, Tapan U, Aksoy S, Harputluoglu H, Kilickap S, Barista I. Liver dysfunction after chemotherapy in lymhoma patients infected with hepatitis C. Eur J Haematol 2008; 80: 381-5.

  40. Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with oncohaematological disease undergoing chemotherapy. Dig Liver Dis 2012; 44: 49-54.

  41. Nooka A, Shenoy PJ, Sinha R, Lonial S, Flowers CR. Hepatitis C reactivation in patients who have diffuse large Bcell lymphoma treated with rituximab: a case report and review of literature. Clin Lymphoma Myeloma Leuk 2011; 11: 379-84.

  42. Da Villa G, Romanò L, Sepe A, Iorio R, Paribello N, Zappa A, Zanetti AR. Impact of hepatitis B vaccination in a higly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine 2007; 25: 3133-6.

  43. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.

  44. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.

  45. Becker N, Schnitzler P, Poffetta P, Brennan P, Foretova L, Maynadié M, Nieters A, et al. Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case-control study Epilymph. J Cancer Res Clin Oncol 2012; 138: 1993-2001.

  46. Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, Chionne P, et al. High prevalence of hepatitis B virus infection in B cell non-Hodgkin lymphoma. Haematologica 2006; 91: 554-7.

  47. Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW, Wang WS, et al. High prevalence of occult hepatitis B virus infection in patients with B-cell non-Hodgkin’s lymphoma. Ann Hematol 2008; 87: 475-80.

  48. Chen D, Sala L, Minisini R, Fabris C, Falleti E, Cerri M, Burlone ME, et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 604-11.

  49. Kang J, Cho JH, Suh CW, Lee DH, Oh HB, Sohn YH, Chi HS, et al. High prevalence of hepatitis B and hepatitis C virus infections in Korean patients with hematopoietic malignancies. Ann Hematol 2011; 90: 159-64.

  50. Boccalini S, Pellegrino E, Tiscione E, Pesavento G, Bechini A, Levi M, Rapi S, et al. Sero-epidemiology of hepatitis B markers in the population of Tuscany, Central Italy, 20 years after the implementation of universal vaccination. Hum Vaccin Immunother 2013; 9: 636-41.

  51. Zanetti AR. Update on hepatitis B vaccination in Italy 10 years after its implementation. Vaccine 2001; 19: 2380-83.

  52. Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World J Hepatol 2016; 8: 385-94.

  53. Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World J Hepatol 2015; 7: 825-30.

  54. Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World J Hepatol 2015; 7: 954-67.

  55. Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 2015; 7: 2344-51.

  56. Yeo W, Chan TC, Leung NW, Lam WY, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.

  57. Mikulska M, Nicolini L, Signori A, Rivoli G, et al. Hepatitis B reactivation in HBsAg-negative/HBcAbpositive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infect 2014; 20: O694-O701.

  58. Mozessohn L, Chan KK, Feld JJ, Hicks LK. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat 2015; 22: 842-9.

  59. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-44.

  60. Sarin SK, Kumar M, Lau GK, Abbas Z, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1-98.

  61. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.

  62. Artz AS, Somerfield MR, Feld JJ, Giusti AF, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010; 28: 3199-202.




2020     |     www.medigraphic.com